Guardant Health is a precision oncology company focused on blood and tissue-based tests to enhance cancer care, offering solutions like the Guardant360 platform for genomic profiling and informing treatment decisions. Operating within the Healthcare sector's Diagnostics & Research industry, the company provides integrated tools for both clinical and biopharmaceutical clients. In its most recent reported quarters, Guardant Health demonstrated a trend of accelerating revenue growth, with Q3 2025 revenue reaching $265.2 million and Q4 2025 revenue at $281.3 million, following $203.5 million in Q1 2025 and $232.1 million in Q2 2025. While revenue has shown consistent increases, the company has consistently missed earnings per share estimates, with EPS figures for Q4 2024, Q1 2025, Q2 2025, Q3 2025, and Q4 2025 reported as -$0.62, -$0.49, -$0.44, -$0.39, and -$0.50 respectively, against estimates of -$0.50, -$0.59, -$0.51, -$0.49, and -$0.72. Historically, Guardant Health has shown a strong year-over-year revenue growth trajectory, with FY2025 sales reaching $982 million, a 33% increase, driven by liquid biopsy adoption, though it continues to incur operating losses. The company has a pattern of beating revenue expectations while missing EPS targets. Recent news highlights significant revenue growth and accelerating adoption of liquid biopsy testing, with FY2026 revenue forecasts around $1.27 billion, alongside a price target of $109.57, despite ongoing losses. Investors will be watching for continued momentum in liquid biopsy adoption and the company's progress toward profitability in upcoming quarters, as well as monitoring its stock's valuation reassessment following recent price action.
